No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS

被引：0
|
作者：
Ryerson, Lana Zhovtis [1 ]
Naismith, Robert T. [2 ]
Krupp, Lauren B. [1 ]
Charvet, Leigh [1 ]
Liao, Shirley [3 ]
Fisher, Elizabeth [3 ]
De Moor, Carl [3 ]
Williams, James R. [3 ]
Licata, Stephanie [3 ]
Campbell, Nolan [3 ]
机构：
[1] NYU, Dept Neurol, NYU Langone Hlth, New York, NY 10003 USA
[2] Washington Univ, Dept Neurol, St Louis, MO 14263 USA
[3] Biogen, Cambridge, MA USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1964
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Extended Interval Dosing of Natalizumab: A Single Center Experience
    Alderazi, Yazan J.
    Campagnolo, Denise
    Bomprezzi, Roberto
    NEUROLOGY, 2011, 76 (09) : A614 - A614
  • [32] NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH® PRESCRIBING PROGRAM
    Ryerson, Lana Zhovtis
    Foley, John
    Chang, Ih
    Kister, Ilya
    Cutter, Gary
    Metzger, Ryan
    Goldberg, Judith D.
    Li, Xiaochun
    Riddle, Evan
    Smirnakis, Karen
    Yu, Bei
    Ren, Zheng
    Hotermans, Christophe
    Ho, Pei-Ran
    Campbell, Nolan
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E29 - E29
  • [33] Natalizumab wearing-off symptoms Patients with MS on extended interval dosing may not "mind the gap"
    Mowry, Ellen M.
    Bourdette, Dennis
    NEUROLOGY, 2019, 93 (17) : 735 - 736
  • [34] Extended interval dosing and reduced dose of natalizumab in a Portuguese population
    Marques, P.
    Correia, I.
    Batista, S.
    Nunes, C.
    Macario, C.
    Campelo, I.
    Sousa, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 782 - 783
  • [35] Evaluation of anti-JC virus index values in multiple sclerosis patients on Natalizumab extended interval dosing and standard interval dosing: an analysis of the TOUCH® prescribing program database
    Foley, J.
    Ryerson, L. Zhovtis
    Chang, I.
    Kister, I.
    Cutter, G.
    Metzger, R.
    Riddle, E.
    Ren, Z.
    Hotermans, C.
    Mason, L.
    Ho, P. -R.
    Campbell, N.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 329 - 330
  • [36] Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world
    Dsilva, Liesel
    McCarthy, Kerry
    Lyons, Jennifer
    Cabigas, Bernadette
    Campbell, Nolan
    Kong, George
    Adams, Bryan
    Kuhelj, Robert
    Singhal, Priya
    Smirnakis, Karen
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (10) : 995 - 1002
  • [37] Clinical efficacy and safety of rituximab extended interval dosing in patients with MS
    Harirchian, Mohammad Hossein
    Nejad, Seyed Ehsan M.
    Paybast, Sepideh
    Jamei, Melika
    Amani, Kiana
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 615 - 616
  • [38] Effectiveness and safety profile of the natalizumab extended interval dosing in a spanish cohort
    Costa-Frossard, L.
    Sainz De La Maza, S.
    Monreal, E.
    Gomez Lopez, A.
    Fernandez-Velasco, J. I.
    Walo Delgado, P.
    Espino, M.
    Villarrubia, N.
    Masjuan, J.
    Villar, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 278 - 278
  • [39] Natalizumab extended-interval dosing in a real-life setting
    Jeantin, Lina
    de la Motte, Marine Boudot
    Deschamps, Romain
    Gueguen, Antoine
    Gout, Olivier
    Lecler, Augustin
    Papeix, Caroline
    Bensa, Caroline
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 450
  • [40] Exploratory PML risk assessment on Extended Interval Natalizumab Dosing.
    Ryerson, Lana Zhovtis
    Foley, John
    Kister, Ilya
    Frohman, Teresa
    Pandey, Krupa
    Lu, Xiaochun
    Goldberg, Judith
    Zuniga-Estrada, Guadalupe
    Hoyt, Tammy
    Jacob, April
    Bacon, Tamar
    Major, Eugene
    Frohman, Elliot
    NEUROLOGY, 2017, 88
12345